25:21
Pr Z. Ivanovic - Mesenchymal stromal cells in anoxia & ischemia: energ. metab. & prolif. capacity
20:48
Dr Giovanni Bénard - A cannabinoid link between mitochondria and memory
23:48
Dr Manuel Rojo - Mitochondrial fusion/fission dynamics and bioenergetics: intricate links
24:21
Dr Raphaël Thuillier - Target and key playor during Ischemia Repefusion in Organ Transplantation
59:24
Pr Martin Brand - Therapeutic suppresion of mitochondrial radical production
X
About
OP2 Drugs SAS ("OP2") is a biotech company that aims at developing innovative life-saving drugs for unmet medical needs, especially in the cardiology field. Our first patented compound, which targets mitochondrial dysfunction, is in preclinical stage, with a strong scientific rational.
Web site : www.linkedin.com/company/op2-drugs-sas-op2/
Videos : Symposium co-organized by OP2 Drugs and IHU Liryc "Mitochondria in Diseases and Therapeutics" (December 5th, 2017) with Professor Martin Brand, Professor Zoran Ivanovic, Dr Giovanni Benard, Dr Manuel Rojo, Dr Raphael Thuillier, Dr Rodrigue Rossignol and Dr Hamid Revzani.
Tags